Neovasc (NASDAQ:NVCN) Research Coverage Started at began coverage on shares of Neovasc (NASDAQ:NVCNGet Rating) (TSE:NVC) in a report issued on Sunday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $125.00 price target on shares of Neovasc in a research report on Friday, March 11th.

NVCN stock opened at $5.78 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 12.88 and a quick ratio of 12.50. The company has a market capitalization of $15.65 million, a PE ratio of -0.48 and a beta of 2.48. The firm’s 50-day moving average is $11.28 and its 200 day moving average is $12.42. Neovasc has a 12 month low of $4.64 and a 12 month high of $28.25.

Neovasc (NASDAQ:NVCNGet Rating) (TSE:NVC) last announced its quarterly earnings data on Thursday, March 10th. The medical equipment provider reported ($2.25) EPS for the quarter, beating the consensus estimate of ($2.50) by $0.25. The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.80 million. Neovasc had a negative net margin of 1,192.20% and a negative return on equity of 50.69%. Sell-side analysts forecast that Neovasc will post -5 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in NVCN. Goldman Sachs Group Inc. acquired a new stake in shares of Neovasc during the second quarter worth $70,000. Citadel Advisors LLC increased its position in shares of Neovasc by 60.5% during the second quarter. Citadel Advisors LLC now owns 118,434 shares of the medical equipment provider’s stock worth $109,000 after acquiring an additional 44,641 shares during the last quarter. UBS Group AG grew its stake in Neovasc by 564.9% in the third quarter. UBS Group AG now owns 34,701 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 29,482 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Neovasc in the fourth quarter valued at approximately $67,000. Finally, Susquehanna International Group LLP acquired a new position in Neovasc in the fourth quarter valued at approximately $26,000. Hedge funds and other institutional investors own 2.42% of the company’s stock.

Neovasc Company Profile (Get Rating)

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.

Further Reading

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.